주식/증권
📈 긍정적
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?
요약
Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum keep investors focused on its growth path.